Patients with moderate or severe hemophilia A can benefit from early prophylactic antihemophilic factor (recombinant) (rAHF), according to an interim analysis presented at the 2021 British Society for Haematology annual meeting. The international AHEAD study is a 6 year non-interventional, prospective trial looking at joint health in patients receiving prophylactic...
research News
The use of intravenous immunoglobulin (IVIG) may provide benefit against infections in subgroups of patients with multiple myeloma (MM), according to a retrospective, single-center crossover study that compared rates of infection in patients with MM during observation compared with those receiving IVIG. The study results were published in Clinical Lymphoma, Myeloma...
LEIDEN, Netherlands & CAMBRIDGE, Mass. — ProQR Therapeutics NV, a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced a collaboration with the Rett Syndrome Research Trust (RSRT) that will focus on the design and development of editing oligonucleotides...
Amsterdam – Collaboration in prostate cancer translational research in Europe is not only vital to sustain the progress achieved in recent years but also to streamline current efforts between researchers and clinicians and avoid duplication or overlaps. This was amongst the goals of the two-day Prostate Cancer Translational Research in...
CARMIEL, Israel – Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research focused healthcare Group (Chiesi...
What is the role of synapses in the development of neurodegenerative diseases and how can nervous tissue be protected from cell death? These are the questions addressed by members of the German National Academy of Sciences Leopoldina as part of their research, with current findings being presented at the Online...
SPOKANE, Wash. – Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells’ resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has spread beyond the prostate. The discovery opens the door to new treatment strategies that could overcome...
Los Angeles, Calif. – Investigators from the UCLA Health Jonsson Comprehensive Cancer Center have identified a protein, called UCHL1, in highly aggressive neuroendocrine carcinomas and neuroblastoma that could potentially be used as a molecular biomarker for diagnosing these cancers and predicting and monitoring responses to therapy. The team also found that using a UCHL1 inhibitor,...
Charleston, SC – When Nancy Klauber-DeMore, M.D., began studying secreted frizzled-related protein 2, or SFRP2, it was as a breast cancer researcher and surgeon. Since she first showed in 2008 that the protein is involved in tumor growth and angiogenesis – the growth of new blood vessels to feed the...
Washington, DC — A team of U.S. investigators led by neuroscientists at Georgetown University Medical Center (GUMC) are steadily uncovering the role that amyloid precursor protein (APP) – the protein implicated in development of Alzheimer’s disease – plays in normal brain function. In the June 10 issue of the Journal...